# Adjuvant Chemotherapy for BTC Based on 3D-PTA

> **NCT07296666** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 98 (estimated)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** Chemotherapy (preferably with a single chemotherapeutic agent) combined with capecitabine (including capecitabine monotherapy: when the preferred drug identified is capecitabine alone).
- **DRUG:** capecitabine alone as adjuvant treatment

## Key facts

- **NCT ID:** NCT07296666
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2027-10
- **Final completion:** 2028-10
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07296666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07296666, "Adjuvant Chemotherapy for BTC Based on 3D-PTA". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07296666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*